The Top Legal Developments for Life Sciences Companies

Life sciences companies are facing an increasingly complex legal climate, and it is easy to miss some of the storms on the horizon. In a recent two-part webinar for Bloomberg BNA, Manatt revealed some of the most significant legal challenges that life sciences leaders need to watch in the year ahead. Participants learned how to prepare for a host of emerging legal developments—and navigate safely through today’s volatile healthcare landscape.

Click Here to View Part 1 and Here to View Part 2. Click Here to Download the Part 1 Presentation and Here to Download the Part 2 Presentation.

The sessions give you the chance to:

  • Discover some of the most important, and surprising, legal developments for life sciences companies.
  • Gain key insights into how critical developments are evolving—including many that come from outside the traditional areas in the sights of life sciences counsel.
  • Explore developments and enforcement trends around antitrust laws, the False Claims Act (FCA), the Foreign Corrupt Practices Act (FCPA), the 340B program, cybersecurity, direct marketing laws, environmental regulation and others.
  • Examine how life sciences companies and their customers can respond to keep their organizations compliant and prepared in a radically changing market.

If you or anyone on your team couldn’t attend the original programs—or want to view them again—we are making them available free, on demand. Click Here to View Part 1 and Here to View Part 2. Click Here to Download the Part 1 Presentation and Here to Download the Part 2 Presentation.